Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) Director Lori Anne Kunkel sold 10,000 shares of the firm's stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $50.49, for a total value of $504,900.00. Following the transaction, the director owned 41,884 shares of the company's stock, valued at $2,114,723.16. This trade represents a 19.27% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Lori Anne Kunkel also recently made the following trade(s):
- On Friday, June 5th, Lori Anne Kunkel sold 10,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $34.54, for a total value of $345,400.00.
Enliven Therapeutics Price Performance
Shares of ELVN stock opened at $50.80 on Thursday. The stock has a market capitalization of $3.09 billion, a PE ratio of -30.42 and a beta of 0.24. The business's 50 day simple moving average is $42.94 and its 200 day simple moving average is $34.37. Enliven Therapeutics, Inc. has a one year low of $14.78 and a one year high of $52.39.
Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.44) by $0.06. As a group, research analysts expect that Enliven Therapeutics, Inc. will post -1.63 earnings per share for the current year.
Institutional Trading of Enliven Therapeutics
Several large investors have recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Enliven Therapeutics by 25.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company's stock valued at $44,000 after acquiring an additional 594 shares in the last quarter. Invesco Ltd. increased its position in shares of Enliven Therapeutics by 4.3% during the second quarter. Invesco Ltd. now owns 21,957 shares of the company's stock worth $440,000 after acquiring an additional 913 shares in the last quarter. BNP Paribas Financial Markets increased its position in shares of Enliven Therapeutics by 33.3% during the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company's stock worth $75,000 after acquiring an additional 930 shares in the last quarter. KBC Group NV acquired a new stake in shares of Enliven Therapeutics in the 1st quarter worth about $38,000. Finally, Swiss National Bank raised its holdings in shares of Enliven Therapeutics by 1.7% in the 4th quarter. Swiss National Bank now owns 64,273 shares of the company's stock worth $990,000 after acquiring an additional 1,100 shares during the last quarter. 95.08% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
A number of brokerages have commented on ELVN. The Goldman Sachs Group upped their price target on shares of Enliven Therapeutics from $41.00 to $59.00 and gave the company a "buy" rating in a research report on Friday, May 8th. HC Wainwright raised their target price on Enliven Therapeutics from $48.00 to $56.00 and gave the stock a "buy" rating in a research note on Thursday, March 26th. Stifel Nicolaus lifted their target price on Enliven Therapeutics from $60.00 to $80.00 and gave the stock a "buy" rating in a report on Wednesday, July 1st. Weiss Ratings reissued a "sell (d-)" rating on shares of Enliven Therapeutics in a research note on Monday, April 20th. Finally, Mizuho increased their price target on Enliven Therapeutics from $45.00 to $62.00 and gave the stock an "outperform" rating in a report on Tuesday, June 2nd. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Enliven Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $67.83.
Read Our Latest Analysis on ELVN
About Enliven Therapeutics
(
Get Free Report)
Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.
The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
